What You Should Know
- Converge Bio has announced a $25M Series A funding round led by Bessemer Venture Partners, bringing its total raised to $30M.
- Moving beyond the "AI promise" gap, the company provides end-to-end AI systems that plug directly into existing drug development workflows, already serving over a dozen pharmaceutical and biotech customers to optimize target discovery and protein manufacturing.
The Systemic Pivot: Bridging the Gap Between Promise and Reality
While
Read More
Drug Discovery | Pharma |News, Analysis, Insights - HIT Consultant
NVIDIA and Eli Lilly Launch AI Co-Innovation Lab to Reinvent Drug Discovery
What You Should Know
- NVIDIA and Eli Lilly and Company have announced a historic $1B, five-year investment to launch an AI co-innovation lab in the San Francisco Bay Area.
- Utilizing the NVIDIA BioNeMo platform and the next-generation Vera Rubin architecture, the lab will co-locate top AI engineers with biology experts to build a "continuous learning system" that integrates agentic wet labs with robotic manufacturing and physical AI.
The "Continuous Learning" Framework: Connecting
Read More
Eli Lilly Taps Chai Discovery’s Frontier AI to Design ‘Computer-Aided’ Biologics
What You Should Know
- Eli Lilly and Company has entered a strategic collaboration with Chai Discovery to deploy frontier AI for the design of novel biologic therapeutics.
- The partnership includes the development of an exclusive, purpose-built AI model trained on Lilly’s proprietary data, leveraging Chai's Chai-2 platform to compress discovery timelines from months to weeks.
The "Zero-Shot" Revolution: Slashing Discovery Timelines
In the world of biologics, antibody design has
Read More
Mount Sinai’s AI Tool “V2P” Predicts Disease Type from Genetic Mutations
What You Should Know:
- Scientists at the Icahn School of Medicine at Mount Sinai have developed a new artificial intelligence tool called V2P (Variant to Phenotype) that identifies not only disease-causing genetic mutations but also predicts the specific diseases they may trigger.
- Published in Nature Communications, this machine learning model improves diagnostic speed and accuracy by linking genetic variants to phenotypic outcomes, moving beyond simple "harmful vs. benign"
Read More
Lunit and Daiichi Sankyo Partner to Accelerate Cancer Biomarker Discovery with AI
What You Should Know:
- Lunit has announced a collaboration with pharmaceutical giant Daiichi Sankyo to integrate its AI-powered Lunit SCOPE digital pathology products into two of Daiichi Sankyo's oncology pipeline programs.
- The partnership will utilize Lunit's SCOPE uIHC and SCOPE IO solutions to analyze pathology slides for quantitative data and immune phenotyping, aiming to discover novel biomarkers and improve patient stratification for clinical trials. This move underscores
Read More
Virtual Clinical Trials: Mayo Clinic’s AI-Powered Solution to Accelerate Heart Failure Drug Discovery
What You Should Know:
- Heart failure is a critical health issue affecting millions of Americans, and despite decades of research, effective treatment options remain limited. Traditional drug development is a slow, costly, and high-risk process.
- Researchers at Mayo Clinic are pioneering a new approach using artificial intelligence (AI) and "virtual clinical trials" to accelerate the discovery of new therapies, particularly by repurposing existing drugs.
An Urgent Need for
Read More
ArcaScience Raises $7M to Advance AI-Powered Drug Benefit-Risk Evaluation
What You Should Know:
- ArcaScience, a Paris, France-based AI Healthtech startup, has announced a $7M seed funding round led by The Moon Venture, with participation from Pléiade Venture, Plug&Play Ventures, Bpifrance, and AKKA Technologies. This marks the company's first institutional funding round, following a €1.3 million pre-seed raise.
- The new funds will be used to expand operations in the U.S. and U.K., launch the company’s first patient-facing solution, and strategically
Read More
Ginkgo, Tangible & Inductive Bio Launch AI-Powered Lab-in-the-Loop Drug Discovery
What You Should Know:
- Ginkgo Bioworks has announced a new strategic partnership with Inductive Bio and Tangible Scientific to make AI-driven "lab-in-the-loop" drug discovery more accessible to the industry.
- The collaboration combines high-throughput experimental workflows, streamlined compound management, and predictive chemistry AI models into one seamless, integrated service. This is designed to help scientists discover better drugs with fewer resources by delivering
Read More
Certara Expands Partnership with Merck to Streamline Drug Development Data Standards
What You Should Know:
- Certara, a global leader in model-informed drug development, today announced an expanded collaboration with Merck, known as MSD outside of the United States and Canada.
- The strategic agreement will see Merck increase its use of the Certara Pinnacle 21 software platform to include a metadata repository and data standards workflow management. This builds upon Merck’s existing technology collaboration with Certara aimed at aiding regulatory
Read More
Eliminating Cancer Treatment Side-Effects Through Targeted Drug Delivery
Last year, the American Cancer Society predicted that in 2024, the US would reach two million annual new cancer cases for the first time in history. This number is staggering and signifies that cancer is truly a disease that impacts many lives each day.
While not all of these cases result in the grueling treatment associated with chemotherapy and radiation, many of those diagnosed will face the difficult road to recovery. Patients in chemotherapy experience a range of symptoms, from
Read More
